https://kstockbriefing.com
![[Disclosure] Samsung Electronics (005930) – Other Management Matters (Voluntary Disclosure) / 2025-02-18](https://kstockbriefing.com/wp-content/uploads/2026/07/포맷변환-삼성전자.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Electronics announced board decisions on its 2025 CSR Matching Grant Fund plan (KRW 11.38B) and a contribution of KRW 2.414B to the Chungnam Samsung Academy educational foundation. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Execution Verification of Fund…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Ocean will convene its regular general meeting of shareholders on March 20, 2025, to vote on financial statement approvals, amendments to the articles of incorporation for dividend process improvements, and the appointment of directors, including Dong-Kwan Kim. 📊 [Key Disclosure Details & Summary of Key…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Ocean’s subsidiary, Hanwha Ocean USA Holdings Corp., decided to participate in a capital increase for its sub-subsidiary, Hanwha Ocean USA International LLC, injecting approximately KRW 153.2B (USD 106.3M). 📊 [Key Disclosure Details & Summary of Key Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Ocean decided to participate in a rights offering for its wholly-owned U.S. subsidiary, Hanwha Ocean USA Holdings Corp., injecting approximately KRW 153.2B (USD 106.3M). 📊 [Key Disclosure Details & Summary of Key Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Capital Injection Schedules and…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Ocean’s U.S. subsidiary (Hanwha Ocean USA International LLC) has decided on a paid-in capital increase of approximately KRW 153.2B to secure operating funds and investment capital for acquiring securities of other corporations. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint)…
![[Disclosure] Celltrion (068270) – Approval of European Commission Marketing Authorization for Stoboclo & Osenvelt (CT-P41, Prolia & Xgeva Biosimilars) / 2025-02-18](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환셀트리온.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received final marketing authorization from the European Commission (EC) for Stoboclo and Osenvelt (CT-P41), biosimilars to Prolia and Xgeva, covering all reference indications across 30 European countries. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of EC Marketing…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received simultaneous approval for both Part 1 (clinical design) and Part 2 (trial sites and execution) of its Phase 3 Clinical Trial Application (CTA) for CT-P55, a Cosentyx biosimilar candidate, from the European Medicines Agency (EMA). 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s…
![[Disclosure] Wonik IPS (240810) – Advance Notice of Financial Results / 2025-02-17](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환원익IPS.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Wonik IPS has officially announced that it plans to disclose its Q4 2024 provisional financial results on February 26, 2025. 📊 [Key Disclosure Contents & Summary Metrics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Provisional Earnings Disclosure and Subsequent Filings This disclosure serves as…
Read More “[Disclosure] Wonik IPS (240810) – Advance Notice of Financial Results / 2025-02-17” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The company will hold IR meetings in Singapore and Seoul for domestic and overseas institutional investors to present its 2025 AI/HBM market outlook, next-generation bonder product lineup, and customer demand strategies. 📊 [Key Disclosure Contents & Summary of Major Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint)…
![[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Holding / 2025-02-14](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환알테오젠.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen is participating in an overseas IR conference in Hong Kong and Singapore from February 17 to February 20, 2025, to present its R&D pipelines, progress on licensed agreements, and long-term growth strategies to foreign institutional investors. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s…
Read More “[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Holding / 2025-02-14” »